[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2009001125A1 - Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. - Google Patents

Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.

Info

Publication number
CL2009001125A1
CL2009001125A1 CL2009001125A CL2009001125A CL2009001125A1 CL 2009001125 A1 CL2009001125 A1 CL 2009001125A1 CL 2009001125 A CL2009001125 A CL 2009001125A CL 2009001125 A CL2009001125 A CL 2009001125A CL 2009001125 A1 CL2009001125 A1 CL 2009001125A1
Authority
CL
Chile
Prior art keywords
treatment
inflammatory diseases
compound
ach
cns
Prior art date
Application number
CL2009001125A
Other languages
English (en)
Inventor
Gregor James Macdonald
Johannes Wilhelmus John F Thuring
Wei Zhuang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39800623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2009001125A1 publication Critical patent/CL2009001125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTO DE FÓRMULA (1), O UN ESTEREOISÓMERO DEL MISMO, DONDE Z, Q, L, SON COMO SE<br /> DEFINE EN LAS REIVINDICACIONES, UNA SAL DE ADICIÓN ACEPTABLE DESDE EL PUNTO DE VISTA FARMACÉUTICO, O<br /> UN HIDRATO O UN SOLVATO DE LA MISMA.<br /> USO DE DICHO COMPUESTO PARA EL TRATAMIENTO O PROFILAXIS DE TRASTORNOS PSICÓTICOS, TRASTORNOS<br /> DEL DETERIORO INTELECTUAL O ENFERMEDADES INFLAMATORIAS.<br /> COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN PORTADOR ACEPTABLE DESDE EL PUNTO DE VISTA<br /> FARMACÉUTICO Y COMO INGREDIENTE ACTIVO UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE DICHO COMPUESTO.<br /> PROCESO PARA PREPARAR DICHA COMPOSICIÓN DONDE UN PORTADOR ACEPTABLE DESDE EL PUNTO DE<br /> VISTA FARMACÉUTICO SE MEZCLA ÍNTIMAMENTE CON UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE DICHO<br /> COMPUESTO.<br /> COMBINACIÓN FARMACÉUTICA QUE COMPRENDE: (A) DICHO COMPUESTO DE FÓRMULA (1), Y (B) UN<br /> AGONISTA DEL RECEPTOR NICOTÍNICO A7<br />  
CL2009001125A 2008-05-09 2009-05-08 Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias. CL2009001125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08155991 2008-05-09

Publications (1)

Publication Number Publication Date
CL2009001125A1 true CL2009001125A1 (es) 2011-02-11

Family

ID=39800623

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001125A CL2009001125A1 (es) 2008-05-09 2009-05-08 Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.

Country Status (14)

Country Link
US (1) US8779158B2 (es)
EP (1) EP2280945B1 (es)
JP (1) JP5486591B2 (es)
KR (1) KR20110007234A (es)
CN (1) CN102015655A (es)
AR (1) AR071763A1 (es)
AU (1) AU2009245715B2 (es)
BR (1) BRPI0912196A2 (es)
CA (1) CA2722805A1 (es)
CL (1) CL2009001125A1 (es)
EA (1) EA018187B1 (es)
ES (1) ES2525132T3 (es)
TW (1) TWI440634B (es)
WO (1) WO2009135944A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2697974C (en) * 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
JP5383788B2 (ja) * 2008-03-19 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体モジュレーターとしての三置換された１，２，４−トリアゾール
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
BR112012005960A2 (pt) 2009-09-17 2016-03-15 Janssen Pharmaceutica Nv n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
PE20140703A1 (es) 2011-02-23 2014-06-13 Lupin Ltd Derivados de heteroarilo como moduladores de nachr alfa 7
SG192939A1 (en) * 2011-02-25 2013-09-30 Janssen Pharmaceutica Nv PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
CN103443075A (zh) 2011-03-31 2013-12-11 鲁平有限公司 作为烟碱型乙酰胆碱受体调节剂的吡咯衍生物在治疗神经变性障碍，例如阿耳茨海默氏病和帕金森氏病中的用途
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
AU2012320581B2 (en) 2011-10-06 2017-03-30 Bayer Intellectual Property Gmbh Heterocyclylpyri (mi) dinylpyrazole as fungicidals
IN2014MN01756A (es) 2012-03-06 2015-07-03 Lupin Ltd
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
CA2913987A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN107652204A (zh) * 2017-09-30 2018-02-02 山东理工大学 一种环氧化物接枝肼还原制备及分散石墨烯的方法
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
US3988348A (en) * 1975-03-14 1976-10-26 American Cyanamid Company 3, OR 5-Aminopyrazolium salts
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
EP0248523B1 (en) * 1986-05-07 1991-10-16 FISONS plc Pyrazoles
GB8611102D0 (en) * 1986-05-07 1986-06-11 Fisons Plc Heterocyclic compounds
JPS6339868A (ja) 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
US4761422A (en) 1986-11-20 1988-08-02 Lusofarmaco Istituto Lusofarmaco D'italia Spa (2-amino-4-aryl-thiazole-5-yl)ethanols and their derivatives having diuretic activity and methods for preparing the same
JPH10504542A (ja) 1994-07-27 1998-05-06 ジー．ディー．サール アンド カンパニー 炎症処置用の置換チアゾール化合物
BR9606546A (pt) 1995-08-02 1998-07-14 Uriach & Cia Sa J Novas carboxamidas com atividade fungicida
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
WO1998028282A2 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
DE69821132T2 (de) 1997-10-27 2004-10-21 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE257827T1 (de) 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
ATE414079T1 (de) 2000-03-01 2008-11-15 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
WO2001074793A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
EP1320365A4 (en) 2000-09-21 2004-03-17 Bristol Myers Squibb Co SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DE60120494T2 (de) 2000-12-22 2006-12-21 Ortho-Mcneil Pharmaceutical, Inc. Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
CN100496493C (zh) 2001-08-13 2009-06-10 詹森药业有限公司 2-氨基-4,5-三取代噻唑基衍生物
EP1441732A2 (en) * 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
CA2474322A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
JP2005524713A (ja) 2002-05-07 2005-08-18 ニューロサーチ、アクティーゼルスカブ 新規ジアザビシクロビアリール誘導体
WO2004096225A2 (en) 2003-04-28 2004-11-11 Ab Science Use of tyrosine kinase inhibitors for treating cerebral ischemia
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
BRPI0410905A (pt) * 2003-06-03 2006-06-27 Novartis Ag inibidores de p-38
CA2532505A1 (en) 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
NZ580450A (en) * 2004-09-17 2011-06-30 Vertex Pharma Diaminotriazole Compounds Useful as Protein Kinase Inhibitors
ZA200703950B (en) 2004-10-21 2008-07-30 Vertex Pharma Triazoles useful as inhibitors of protein kinases
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
WO2007031440A2 (en) 2005-09-13 2007-03-22 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CA2697974C (en) * 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JP5383788B2 (ja) * 2008-03-19 2014-01-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ニコチン性アセチルコリン受容体モジュレーターとしての三置換された１，２，４−トリアゾール
EA018113B1 (ru) 2008-04-17 2013-05-30 Глэксо Груп Лимитед Индолы в качестве модуляторов никотинового рецептора ацетилхолина подтипа альфа-71
BR112012005960A2 (pt) * 2009-09-17 2016-03-15 Janssen Pharmaceutica Nv n-fenil-1-(4-piridinil)-1h-pirazol-3-aminas substituídas
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
SG192939A1 (en) 2011-02-25 2013-09-30 Janssen Pharmaceutica Nv PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR

Also Published As

Publication number Publication date
CA2722805A1 (en) 2009-11-12
KR20110007234A (ko) 2011-01-21
TWI440634B (zh) 2014-06-11
EA201071288A1 (ru) 2011-04-29
AU2009245715A1 (en) 2009-11-12
JP2011519901A (ja) 2011-07-14
EP2280945A1 (en) 2011-02-09
AU2009245715B2 (en) 2014-01-09
US20110065683A1 (en) 2011-03-17
US8779158B2 (en) 2014-07-15
AR071763A1 (es) 2010-07-14
BRPI0912196A2 (pt) 2015-10-06
ES2525132T3 (es) 2014-12-17
WO2009135944A1 (en) 2009-11-12
TW201006812A (en) 2010-02-16
EA018187B1 (ru) 2013-06-28
JP5486591B2 (ja) 2014-05-07
CN102015655A (zh) 2011-04-13
EP2280945B1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
CL2009001125A1 (es) Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
NI201400031A (es) Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio
AR068919A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales.
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
EA201190142A1 (ru) Производные пиразола, используемые в качестве антагонистов рецептора ccr4
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
TN2013000257A1 (en) Immunosuppressant formulations
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
TW200800984A (en) New compounds
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
RS54420B1 (en) FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT
MY162554A (en) Novel benzamide derivatives
SV2011003896A (es) Pirrolidinas
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
JOP20200127A1 (ar) مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية